Summit Therapeutics Inc. (SMMT)
NASDAQ (NMS) NASDAQ (NMS) Primary 
XMEX 
SMMT Inks Deal With AZN-Daiichi to Study Ivonescimab + Datroway Combos
Summit is teaming up with AstraZeneca and Daiichi to test ivonescimab with Datroway across breast and lung cancers, broadening its potential.
SMMT Stock Soars on NSCLC Drug Survival Data Beating Keytruda in China
Summit Therapeutics stock jumps 17% after ivonescimab showed a significant overall survival benefit over Keytruda in a China phase III lung cancer study.
November 14 Is The Make-Or-Break Moment For Summit Therapeutics' Cancer Bet
Summit Therapeutics is positioned as a high-conviction buy into the November 2026 FDA PDUFA decision for ivonescimab in NSCLC. SMMT's ivonescimab demonstrates robust PFS and statistically significant OS benefits in multiple Phase III trials, supporting best-in-class potential versus PD-1 monotherapy. Financials reflect intentional capital deployment, with $690M+ cash and 4–5 quarters of runway to fund late-stage clinical catalysts and regulatory milestones.
SMMT Rises on Akeso's Win in Phase III Biliary Tract Cancer Study
Summit gains as positive HARMONi-GI1 data show ivonescimab's OS benefit in biliary tract cancer, expanding its potential beyond NSCLC.
SMMT's Q2 Loss Wider Than Expected, Ivonescimab Development in Focus
Summit posts a wider Q2 loss with no revenues as ivonescimab advances through late-stage studies, undergoes FDA review & gains new development collaborations.
Summit Therapeutics Inc. (SMMT) Q2 2026 Earnings Call Transcript
Summit Therapeutics Inc. (SMMT) Q2 2026 Earnings Call Transcript
Summit Therapeutics Q2 Earnings Call Highlights
Summit Therapeutics NASDAQ: SMMT executives used the company's latest earnings call to emphasize updated survival data for ivonescimab, outline the timing of key late-stage trial readouts and detail the company's cash position as it prepares for a potential U.S. regulatory decision later this year.
SMMT Shares Updated Ivonescimab Survival Data From NSCLC Study
Summit announces updated HARMONi overall survival data and partners with Arcus to test ivonescimab in kidney cancer, expanding its late-stage development.
Summit to Divest Late-Stage Antibiotic Drug to Biossil in $105M Deal
SMMT divests investigational antibiotic ridinilazole to Biossil for upfront cash, milestone payments and royalties as it sharpens its focus on oncology.
Summit Therapeutics: High-Volatility, Catalyst-Driven Binary Bet
Summit Therapeutics is a highly volatile, single-asset company with a binary outcome. SMMT exhibits unusually concentrated ownership and heightened short interest, creating conditions for a short squeeze to take place. Recent pullbacks, driven by mixed market receptions to events do not fundamentally alter the investment narratives, present investors with an attractive entry point ahead of key catalysts.
Summit Therapeutics Inc. (SMMT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Summit Therapeutics Inc. (SMMT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
All You Need to Know About Summit Therapeutics (SMMT) Rating Upgrade to Buy
Summit Therapeutics (SMMT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
